ImmunoGen Inc. said Thursday that Amgen Inc. licensed rights to a second potential cancer-treatment from the company for $1 million upfront.

Moody's Investors Service issued a negative opinion on the pharmaceutical industry Thursday, saying drugmaker credit ratings will be under pressure until early 2012 because they won't be able to fully replace revenue from best-sellers that go off-patent.

A large study being published in a major medical journal says certain kidney disease patients who get the drug Aranesp to treat anemia-related fatigue may be at greater risk of having a stroke.

New York Attorney General Andrew Cuomo and 14 other states are filing a lawsuit against Amgen, alleging that the biotech company was offering kickbacks to medical providers to increase the sale of its anemia drug Aranesp.

Stocks advanced Thursday as investors seemed to focus more on some big-name earnings beats and a rise in leading indicators instead of a disappointing jobless report. Travelers and MMM led the Dow.

Stocks advanced Thursday as investors seemed to focus more on some big-name earnings beats and a rise in leading indicators instead of a disappointing jobless report.

Stocks slipped Thursday as investors weighed a disappointing jobless-claims report and some encouraging earnings reports.

Earnings continue to come in largely above expectations, but other factors are waylaying the stock market's recent advances - ranging from Walmart's price cuts to analyst Richard Bove's downgrade of Wells Fargo to rising oil prices. 

Amgen reported quarterly results that outpaced what Wall Street was expecting, and the company boosted its outlook for its full-year profit. But the company's shares declined in extended trading.

Stocks finished lower after well-known banking analyst Dick Bove downgraded his rating on Wells Fargo.

Stocks advanced Wednesday as investors were encouraged by a few earnings reports, including Morgan Stanley, Yahoo and SanDisk. The VIX, widely considered the best gauge of fear in the market, dropped to just above 20.

Stocks opened lower Wednesday as a raft of companies beating earning estimates but failed to impress investors.

Earnings season continues in earnest Wednesday, as we roll on with a week that will ultimately see 25 percent of the S&P 500 report their quarterly numbers. 

Markets are likely to end the year higher and investors need some strong, blue-chip stocks in their portfolios, to counteract the volatility shown by cyclical shares, Bob Doll, global chief investment officer of equities at BlackRock, told CNBC Tuesday.

A first-of-its-kind osteoporosis drug lowers the risk of bone fractures better than some existing treatments, two studies suggest.